Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction, rationale and design of the trial

  • Mathur, Anthony|||0000-0001-7941-9653
  • Arnold, Roman
  • Assmus, Birgit
  • Bartunek, Jozef
  • Belmans, Ann
  • Bönig, Halvard|||0000-0003-0088-2675
  • Crea, Filippo|||0000-0001-9404-8846
  • Dimmeler, Stefanie
  • Dowlut, Sheik
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • Galiñanes, Manuel|||0000-0002-0888-976X
  • García-Dorado, David|||0000-0002-1126-1279
  • Hartikainen, Juha|||0000-0003-0847-107X
  • Hill, Jonathan
  • Hogardt-Noll, Annette
  • Homsy, Christian
  • Janssens, Stefan
  • Kala, Petr
  • Kastrup, Jens|||0000-0002-3668-5393
  • Martin, John
  • Menasche, Philippe
  • Miklik, Roman
  • Mozid, Abdul
  • San Román, José Alberto|||0000-0003-0764-0839
  • Sanz-Ruiz, Ricardo
  • Tendera, Michal
  • Wojakowski, Wojtek|||0000-0002-3681-5207
  • Ylä-Herttuala, Seppo|||0000-0001-7593-2708
  • Zeiher, Andreas Michael|||0000-0003-1711-5819
Over the past 13 years bone marrow-derived mononuclear cells () have been widely investigated for clinical efficacy in patients following acute myocardial infarction (). These early phase trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. The phase trial has therefore been designed to demonstrate that intracoronary infusion of is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left ventricular ejection fraction after successful reperfusion for -elevation (powered with the aim of detecting a 25% reduction in all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase study aiming to enrol approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection (≤45%) following successful reperfusion for will be randomized to treatment or control group in a 1:1 ratio. The treatment group will receive intracoronary infusion of 2-8 days after successful reperfusion for added on top of optimal standard of care. The control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The trial is pivotal and the largest trial to date of in patients with impaired left ventricular function following . The aim of the trial is to provide a definitive answer as to whether reduce all-cause mortality in this group of patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction, the BAMI trial

  • Mathur, Anthony|||0000-0001-7941-9653
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • Bartunek, Jozef
  • Belmans, Ann
  • Crea, Filippo|||0000-0001-9404-8846
  • Dowlut, Sheik
  • Galiñanes, Manuel|||0000-0002-0888-976X
  • Good, Marie-Claire
  • Hartikainen, Juha|||0000-0003-0847-107X
  • Hauskeller, Christine
  • Janssens, Stefan
  • Kala, Petr
  • Kastrup, Jens|||0000-0002-3668-5393
  • Martin, John
  • Menasché, Philippe
  • Sanz-Ruiz, Ricardo
  • Ylä-Herttuala, Seppo|||0000-0001-7593-2708
  • Zeiher, Andreas Michael|||0000-0003-1711-5819
Bone marrow-derived mononuclear cell (BM-MNC) therapy may improve myocardial recovery in patients following acute myocardial infarction (AMI), though existing trial results are inconsistent. Originally an open-label, multicentre Phase III trial, BAMI was designed to demonstrate the safety and efficacy of intracoronary infusion of BM-MNCs in reducing the time to all-cause mortality in patients with reduced left ventricular ejection fraction (LVEF, ≤45%) after primary angioplasty (PPCI) for ST-elevation AMI. Unexpectedly low recruitment means the trial no longer qualifies as a hypothesis-testing trial, but is instead an observational study with no definitive conclusions possible from statistical analysis. In total, 375 patients were recruited: 185 patients were randomized to the treatment arm (intracoronary infusion of BM-MNCs 2-8 days after PPCI) and 190 patients to the control arm (optimal medical therapy). All-cause mortality at 2 years was 3.26% [6 deaths; 95% confidence interval (CI): 1.48-7.12%] in the BM-MNC group and 3.82% (7 deaths; 95% CI: 1.84-7.84%) in the control group. Five patients (2.7%, 95% CI: 1.0-5.9%) in the BM-MNC group and 15 patients (8.1%, CI : 4.7-12.5%) in the control group were hospitalized for heart failure during 2 years of follow-up. Neither adverse events nor serious adverse events differed between the two groups. There were no patients hospitalized for stroke in the control group and 4 (2.2%) patients hospitalized for stroke in the BM-MNC group. Although BAMI is the largest trial of autologous cell-based therapy in the treatment of AMI, unexpectedly low recruitment and event rates preclude any meaningful group comparisons and interpretation of the observed results.